Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

Brentuximab vedotin (BV) was initially approved in Japan for the treatment of relapsed/refractory (R/R) CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). As requested by the Japanese Ministry of Health, Labour and Welfare, we conducted a post-marketing surveill...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Hematol
Main Authors: Izutsu, Koji, Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Sakamoto, Shigeru, Nishimura, Masanori, Hoshino, Miyako
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Singapore 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779085/
https://ncbi.nlm.nih.gov/pubmed/33392974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-020-03039-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados